EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
TB47 (pyrazolo[1,5-a]pyridine-3-carboxamides)
CLASS
Imidazopyridine amide
TARGET PROTEIN
QcrB Cytochrome bc1:aa3
MECHANISM OF ACTION
Bactericidal ctivity (can block the cytochrome bc1 complex, thereby causing a reduction of intracellular ATP and eventually inhibiting the growth of M. ulcerans)
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Investigational
MODE OF ADMINISTRATION
Oral
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/33777679/ https://pubmed.ncbi.nlm.nih.gov/33152940/
EXTERNAL LINKS
PubChem Compound 122188597
REFERENCE
Gaoa, Y., Hameed, H. M. A., Liua, Y., Guoa, L., Fanga, C., Tiana, X., Liua, Z., Wanga, S., Lua, Z., Islama, M. M., & Zhang, T. (2021). Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans. Acta Pharmaceutica Sinica. B, 11(3), 738?749. https://doi.org/10.1016/J.APSB.2020.11.007 Yu, W., Chiwala, G., Gao, Y., Liu, Z., Sapkota, S., Lu, Z., Guo, L., Khan, S. A., Zhong, N., & Zhang, T. (2020). TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice. Biomedicine & Pharmacotherapy, 131, 110782. https://doi.org/10.1016/J.BIOPHA.2020.110782